【摘要】 采用抗-HBs人血清加乙肝疫苗、HBIG加乙肝疫苗的联合免疫、以阻断HBV母婴传播的临床观察。试验组与对照组对比差异非常显著(P<0.005)。更多还原

【Abstract】 We selected the infants born to mothers with HBeAg positive and divided them into three groups. In group Ⅰ: the neonates recieving HBIG and HBVaccine. In group Ⅱ: the neonates recieving anti-HBs and HBvaccine. In group Ⅲ: the neonates were compared with group Ⅰ.Ⅱ The results showed: HBsAg positive in 91.7% (22/24) of infants of group Ⅲ; In 20% (2/10) of infants of group Ⅰ and in 12.5%(2/16) of infants of group Ⅱ. All of these HBsAg positive infants become persitent carriers. The difference between group Ⅲ and group Ⅰ,Ⅱ. was statistically significant P<0.005. Protective efficacy group Ⅰ is 78.2%. and group Ⅱ is 85.5%. These results indicate that immune response in neonates to HBIG or anti-HBs and HBvaccine are valid and it’s efficacy in interuption of perinatal transmission of HBV carrier state is promising.更多还原